logo
CNC Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of September 8, 2025 Deadline in Securities Fraud Class Action Lawsuit Against Centene Corporation (CNC)

CNC Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of September 8, 2025 Deadline in Securities Fraud Class Action Lawsuit Against Centene Corporation (CNC)

RADNOR, PA - August 8, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Centene Corporation ('Centene') ( NYSE: CNC ) on behalf of those who purchased or otherwise acquired Centene securities between December 12, 2024, and June 30, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is September 8, 2025.
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered Centene losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/centene-corporation?utm_source=NewMediaWire&utm_medium=PR
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].
DEFENDANTS' ALLEGED MISCONDUCT:
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Centene's marketplace share showed lower-than-anticipated enrollment and increased aggregate market morbidity; and (2) as a result, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
THE LEAD PLAINTIFF PROCESS:
Centene investors may, no later than September 8, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Centene investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/centene-corporation?utm_source=NewMediaWire&utm_medium=PR
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness
Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness

Yahoo

time21 minutes ago

  • Yahoo

Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness

We recently published . Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)'s shares have lost 16% year-to-date as investors continue to be disappointed by the dropping revenue of its GARDASIL HPV drug in China. They are also worried about the patent expiration of the firm's mega cancer drug KEYTRUDA and wondering whether Merck & Co., Inc. (NYSE:MRK) will be able to follow up with an equally successful successor. However, the shares did gain 3% this week after Pfizer announced that its bladder cancer drug PADCEV improves survival rates when paired with KEYTRUDA. Cramer was impressed as he commented: 'Look at Merck. I mean, Saint Merck. What a tough, what a tough.' Photo by National Cancer Institute on Unsplash Here are his earlier comments about Merck & Co., Inc. (NYSE:MRK): 'Well, this GARDASIL, when is it? The Chinese are not really helping them sell, because you would have thought the Chinese would. . .and then you've got the KEYTRUDA, you know the patent cliff coming up. . .it's amazing, but they are talking about their animal division. When you're talking about your animal division you don't have enough [inaudible] to talk.' While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Salesforce, Inc. (CRM)'s CEO Is Pushing Back Against The AI Vs Enterprise Software Narrative, Says Jim Cramer
Salesforce, Inc. (CRM)'s CEO Is Pushing Back Against The AI Vs Enterprise Software Narrative, Says Jim Cramer

Yahoo

time21 minutes ago

  • Yahoo

Salesforce, Inc. (CRM)'s CEO Is Pushing Back Against The AI Vs Enterprise Software Narrative, Says Jim Cramer

We recently published . Salesforce, Inc. (NYSE:CRM) is one of the stocks Jim Cramer recently discussed. Salesforce, Inc. (NYSE:CRM)'s shares have lost 28% year-to-date as the firm has struggled to retain investor attention in the age of AI. Like investors are hawkishly watching its revenue pipeline and revenue commitments for the rest of the year – a fact which led the stock to dip 5% in May after its fiscal first quarter earnings. Cramer discussed the sentiment surrounding enterprise software stocks and CEO Marc Benioff's attempts to counter it: '. . .and I think that people should recognize that these companies are all being viewed as, let's say carrion, because what's happened is this that you can develop your own stuff that is better. Now Marc Benioff is doing some pushback on that by the way, he's saying that if you're doing process stuff, you're not going to be able to, maybe creative, that would be Adobe. But not, Salesforce. So Marc's pushing back Salesforce. . .' Pixabay/Public Domain Here are his previous remarks about Salesforce, Inc. (NYSE:CRM): 'Okay, so Salesforce is a little tough right now because right now, the enterprise software companies are all coming down. I have not been recommending the stock hard. I want to see what happens with the quarter. I wish I could be more definite, but sometimes it's better just to say I don't have a handle on it.' While we acknowledge the potential of CRM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer
Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer

Yahoo

time21 minutes ago

  • Yahoo

Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer

We recently published . Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE)'s shares jumped by 1.8% earlier this week after the firm announced that its bladder cancer drug Padcev helped improve bladder cancer survival rates when combined with Merck's well-known cancer treatment, KEYTRUDA. The gains were a much-needed boost to the stock, which is still down by 5.6% year-to-date, as the firm has struggled to grow revenue in a turnaround effort led by CEO Albert Bourla. Cramer lamented that Pfizer Inc. (NYSE:PFE)'s stock didn't move higher on the news: 'Bladder cancer. Now that is left over from the Seagen. The Seagen deal, that was supposed to be very, very important. They spent a fortune on Seagen. And I thought the [inaudible] I thought would be a little more just positive. People are not buying the stock. People just feel like, Pfizer comes up with good thing, good thing, good thing, and no one seems to, David, take it as gospel.' Copyright: kadmy / 123RF Stock Photo Cramer discussed Pfizer Inc. (NYSE:PFE) ahead of its earnings: 'There's another one, that I'm not so sure of, reporting at the same time, though, Pfizer. We need to see some really dramatic results here from the clinical trials like the ones that Pfizer picked up when they bought the Seagen at the end of 2023. It's enough time to see more than we've seen already, I gotta tell you that. And they better hurry up because the shareholder base is getting very restive, and who knows what the president has… against this industry.' While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store